Autolus Therapeutics plc (AUTL) Ownership
AUTL ownership summary
as of October 17, 2026- Institutions
- 63.4% of shares outstanding
- Insiders
- 18.09% of shares outstanding
- Shares outstanding
- 266.2M
- Float
- 102.9M shares available to trade
- Short interest
- 4.87% 8.4M shares short
- Days to cover
- 5.29 short interest up 0.9% vs prior month
- Institutions 63.42%
- Insiders 18.09%
- Other investors 18.49%
AUTL top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Mak Capital One LLC | 12.63% | 33.6M | $53.8M | — | June 30, 2026 |
| 2 | Blackstone Inc | 7.70% | 20.5M | $32.8M | — | June 30, 2026 |
| 3 | Syncona Portfolio Ltd. | 6.25% | 16.6M | $26.6M | — | June 30, 2026 |
| 4 | Armistice Capital, LLC | 5.64% | 15.0M | $24.0M | −800,000 (−5.1%) | June 30, 2026 |
| 5 | Polygon Management Ltd | 3.57% | 9.5M | $15.2M | — | June 30, 2026 |
| 6 | Schroder Investment Management Group | 2.94% | 7.8M | $12.5M | −1.7M (−17.5%) | June 30, 2026 |
| 7 | Frazier Life Sciences Management, L.P. | 1.67% | 4.4M | $7.1M | — | June 30, 2026 |
| 8 | BNP Paribas Investment Partners SA | 1.26% | 3.4M | $5.4M | — | June 30, 2026 |
| 9 | LAURION CAPITAL MANAGEMENT LP | 1.25% | 3.3M | $5.3M | — | June 30, 2026 |
| 10 | Renaissance Technologies Corp | 0.75% | 2.0M | $3.2M | −314,799 (−13.7%) | June 30, 2026 |
| 11 | Bank of America Corp | 0.60% | 1.6M | $2.6M | −239,579 (−13.0%) | June 30, 2026 |
| 12 | BlackRock Inc | 0.60% | 1.6M | $2.6M | +122,726 (+8.3%) | June 30, 2026 |
| 13 | UBS Group AG | 0.57% | 1.5M | $2.4M | +211,212 (+16.2%) | June 30, 2026 |
| 14 | Morgan Stanley - Brokerage Accounts | 0.47% | 1.3M | $2.0M | +319,009 (+33.9%) | June 30, 2026 |
| 15 | Millennium Management LLC | 0.46% | 1.2M | $2.0M | +1.0M (+498.3%) | June 30, 2026 |
| 16 | Cetera Investment Advisers | 0.43% | 1.2M | $1.9M | +28,250 (+2.5%) | June 30, 2026 |
| 17 | Balyasny Asset Management LLC | 0.37% | 973K | $1.6M | +1,057 (+0.1%) | June 30, 2026 |
| 18 | JPMorgan Chase & Co | 0.34% | 913K | $1.5M | −22,164 (−2.4%) | June 30, 2026 |
| 19 | Alphabet Inc | 0.26% | 698K | $1.1M | — | June 30, 2026 |
| 20 | Citadel Advisors Llc | 0.26% | 696K | $1.1M | +236,486 (+51.5%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 7 holders added 1.9M shares and 5 cut 3.0M.
AUTL top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | International Biotechnology Ord | 2.45% | 6.5M | $10.4M | −686,636 (−9.5%) | August 31, 2026 |
| 2 | AXA Framlington Health Fund - R Income | 1.26% | 3.4M | $5.4M | — | July 31, 2026 |
| 3 | iShares Biotechnology ETF | 0.50% | 1.3M | $2.1M | −10,128 (−0.8%) | September 30, 2026 |
| 4 | JPM Thmtcs Gentc Thrps C2 dist USD | 0.33% | 880K | $1.4M | +9,874 (+1.1%) | August 31, 2026 |
| 5 | MGTS Sentinel Navigator B Acc | 0.11% | 287K | $459,438 | — | July 31, 2026 |
| 6 | Ashburton Global Equity Growth D USD | 0.11% | 284K | $454,590 | — | September 30, 2026 |
| 7 | Tema Oncology ETF | 0.10% | 274K | $437,787 | — | September 30, 2026 |
| 8 | ERSTE STOCK BIOTEC EUR R01 A | 0.07% | 195K | $312,000 | — | August 31, 2026 |
| 9 | SVS Aubrey Citadel Fund A GBP Acc | 0.07% | 180K | $288,000 | +50,000 (+38.5%) | April 30, 2026 |
| 10 | MGTS Downing Diversified Opps F GBP Acc | 0.07% | 180K | $288,000 | — | July 31, 2026 |
| 11 | iShares Nasdaq US Biotech ETF USD Acc | 0.06% | 172K | $275,958 | +1,484 (+0.9%) | September 30, 2026 |
| 12 | State Street® SPDR® S&P® Intl Sm Cp ETF | 0.04% | 102K | $163,128 | — | September 30, 2026 |
| 13 | Galileo - Biotech Innovation Fund S USD | 0.04% | 100K | $160,000 | — | March 31, 2026 |
| 14 | Invesco NASDAQ Future Gen 200 ETF | 0.02% | 51K | $81,186 | — | September 30, 2026 |
| 15 | China Universal NASDAQ Bio-Tch ETF(QDII) | 0.01% | 32K | $51,080 | −762 (−2.3%) | June 30, 2026 |
| 16 | ActivePassive International Equity ETF | 0.01% | 32K | $50,773 | — | September 30, 2026 |
| 17 | HealthInvest S&M Cap Healthcare C | 0.01% | 23K | $37,022 | +23,139 (0.0%) | January 31, 2026 |
| 18 | Invesco Nasdaq Biotechnology ETF | 0.01% | 14K | $22,688 | +644 (+4.8%) | September 30, 2026 |
| 19 | Fidelity Nasdaq Composite Index | 0.01% | 13K | $21,370 | −116,468 (−89.7%) | August 31, 2026 |
| 20 | Pharus Sicav Asian Value Niches Q | <0.01% | 11K | $17,600 | — | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
AUTL shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns AUTL
Institutional investors own 63.4% of Autolus Therapeutics's shares and insiders 18.09%. The largest holder is Mak Capital One LLC with 12.63% of the shares (33.6M), as of June 30, 2026. Among the top 20 institutions, 7 added shares and 5 reduced their stake in the latest filings. Short interest is 4.87% of the float, or 5.29 days of average trading volume. The share count rose 2,168.6% since 2016.
Related: AUTL analyst forecast, AUTL key metrics. See the AUTL stock overview for the latest quote and news.
AUTL ownership FAQ
Who owns the most Autolus Therapeutics stock?
The largest shareholders of Autolus Therapeutics are Mak Capital One LLC (12.63%), Blackstone Inc (7.70%), Syncona Portfolio Ltd. (6.25%), Armistice Capital, LLC (5.64%), Polygon Management Ltd (3.57%).
What percentage of Autolus Therapeutics is owned by institutions?
Institutions hold 63.4% of Autolus Therapeutics's shares outstanding; insiders hold 18.09%.
Which funds own Autolus Therapeutics?
The largest fund holders of Autolus Therapeutics are International Biotechnology Ord (2.45%), AXA Framlington Health Fund - R Income (1.26%), iShares Biotechnology ETF (0.50%), JPM Thmtcs Gentc Thrps C2 dist USD (0.33%), MGTS Sentinel Navigator B Acc (0.11%).
What is Autolus Therapeutics's short interest?
8.4M shares of Autolus Therapeutics were sold short, 4.87% of the float; at the average daily volume it would take 5.29 days to cover.
How many shares of Autolus Therapeutics are outstanding?
Autolus Therapeutics has 266.2M shares outstanding, of which 102.9M are in the public float.